Cristina Scarpecci
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Cristina Scarpecci has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Giovanna Poce
Department of Drug Chemistry and Technologies, Sapienza University of Rome, Italy
3 shared publications - Mariangela Biava
Department of Chemistry and Technologies of Drug, Sapienza University of Rome, Piazzale A. Moro, 5, 00185 Rome, Italy
3 shared publications - Sara Consalvi
Department of Chemistry and Technologies of Drug, Sapienza University of Rome, Piazzale A. Moro, 5, 00185 Rome, Italy
2 shared publications - Federico Appetecchia
Department of Chemistry and Technologies of Drug, Sapienza University of Rome, Piazzale A. Moro 5, 00185 Rome, Italy
1 shared publication Sara Consalvi
Department of Chemistry and Technologies of Drug, Sapienza University of Rome, Piazzale A. Moro 5, 00185 Rome, Italy
1 shared publication
Latest Publications
- 1 November 2020
- Published by Taylor & Francis in Future Microbiology
- Vol. 15 (17) , 1607-1609
Overcoming Drug resistance in TB: An Update
- 1 November 2020
- Published by Taylor & Francis in Future Microbiology
- Vol. 15 (17) , 1607-1609
Overcoming Drug resistance in TB: An Update
- Open Access
- 31 August 2020
- Published by MDPI AG in Pharmaceuticals
- Vol. 13 (9) , 227
SAR Analysis of Small Molecules Interfering with Energy-Metabolism in Mycobacterium tuberculosis
Tuberculosis remains the world’s top infectious killer: it caused a total of 1.5 million deaths and 10 million people fell ill with TB in 2018. Thanks to TB diagnosis and treatment, mortality has been falling in recent years, with an estimated 58 million saved lives between 2000 and 2018. However, the emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Mtb strains is a major concern that might reverse this progress. Therefore, the development of new drugs acting upon novel mechanisms of action is a high priority in the global health agenda. With the approval of bedaquiline, which targets mycobacterial energy production, and delamanid, which targets cell wall synthesis and energy production, the energy-metabolism in Mtb has received much attention in the last decade as a potential target to investigate and develop new antimycobacterial drugs. In this review, we describe potent anti-mycobacterial agents targeting the energy-metabolism at different steps with a special focus on structure-activity relationship (SAR) studies of the most advanced compound classes.
- 31 August 2020
- Published by MDPI AG in Pharmaceuticals
- Vol. 13 (9) , 227
Open AccessSAR Analysis of Small Molecules Interfering with Energy-Metabolism in Mycobacterium tuberculosis
Tuberculosis remains the world’s top infectious killer: it caused a total of 1.5 million deaths and 10 million people fell ill with TB in 2018. Thanks to TB diagnosis and treatment, mortality has been falling in recent years, with an estimated 58 million saved lives between 2000 and 2018. However, the emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Mtb strains is a major concern that might reverse this progress. Therefore, the development of new drugs acting upon novel mechanisms of action is a high priority in the global health agenda. With the approval of bedaquiline, which targets mycobacterial energy production, and delamanid, which targets cell wall synthesis and energy production, the energy-metabolism in Mtb has received much attention in the last decade as a potential target to investigate and develop new antimycobacterial drugs. In this review, we describe potent anti-mycobacterial agents targeting the energy-metabolism at different steps with a special focus on structure-activity relationship (SAR) studies of the most advanced compound classes.
- 1 December 2019
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 29 (23) , 126731
Mycobacterial tryptophan biosynthesis: A promising target for tuberculosis drug development?
- 1 December 2019
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 29 (23) , 126731
Mycobacterial tryptophan biosynthesis: A promising target for tuberculosis drug development?